GAMMA Investing LLC Raises Stake in Certara, Inc. (NASDAQ:CERT)

GAMMA Investing LLC boosted its stake in shares of Certara, Inc. (NASDAQ:CERT) by 442.2% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 8,421 shares of the company’s stock after purchasing an additional 6,868 shares during the period. GAMMA Investing LLC’s holdings in Certara were worth $90,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its stake in Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock valued at $46,000 after acquiring an additional 2,076 shares during the last quarter. KBC Group NV raised its holdings in shares of Certara by 48.2% in the 3rd quarter. KBC Group NV now owns 4,873 shares of the company’s stock worth $57,000 after purchasing an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new position in Certara in the second quarter valued at approximately $152,000. Algert Global LLC bought a new position in Certara during the second quarter valued at $156,000. Finally, MQS Management LLC purchased a new stake in Certara in the second quarter worth $162,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Stock Performance

NASDAQ:CERT opened at $10.61 on Friday. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87. The business’s fifty day moving average is $10.84 and its 200 day moving average is $12.01. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The firm has a market cap of $1.71 billion, a price-to-earnings ratio of -53.05, a PEG ratio of 5.86 and a beta of 1.52.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.02. Certara had a positive return on equity of 3.43% and a negative net margin of 8.34%. The firm had revenue of $94.80 million for the quarter, compared to analysts’ expectations of $95.51 million. During the same period in the prior year, the business posted $0.06 earnings per share. The company’s revenue was up 10.7% on a year-over-year basis. Research analysts predict that Certara, Inc. will post 0.28 EPS for the current year.

Wall Street Analyst Weigh In

CERT has been the topic of a number of recent research reports. UBS Group raised Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a research report on Friday, September 27th. Barclays lowered their price objective on Certara from $14.00 to $12.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 7th. Finally, Robert W. Baird cut their target price on shares of Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research report on Tuesday, November 5th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.